NASDAQ:TNXP Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis $12.77 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$12.89 +0.12 (+0.95%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tonix Pharmaceuticals Stock (NASDAQ:TNXP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tonix Pharmaceuticals alerts:Sign Up Key Stats Today's Range$12.75▼$14.0150-Day Range$12.03▼$16.0852-Week Range$11.60▼$69.97Volume617,970 shsAverage Volume399,540 shsMarket Capitalization$203.57 millionP/E RatioN/ADividend YieldN/APrice Target$22.00Consensus RatingModerate Buy Company Overview Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents. Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD. The company is conducting late-stage clinical trials to assess safety and efficacy in people who experience chronic pain and disrupted sleep due to these conditions. In addition to its CNS portfolio, Tonix is advancing live-virus vaccine candidates against orthopoxviruses, including those that could be used for smallpox or monkeypox, and is exploring development of vaccines against other biothreat agents. Headquartered in New York, Tonix Pharmaceuticals leverages in-house research and collaborations with academic institutions and government agencies to advance its pipeline. The company was co-founded and is led by Seth H. Lederman, M.D., who serves as President and Chief Executive Officer. Under Dr. Lederman’s direction, Tonix continues to progress multiple programs through clinical development while maintaining a focus on unmet medical needs in both therapeutic and vaccine arenas.AI Generated. May Contain Errors. Read More Tonix Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreTNXP MarketRank™: Tonix Pharmaceuticals scored higher than 64% of companies evaluated by MarketBeat, and ranked 299th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingTonix Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialTonix Pharmaceuticals has a consensus price target of $22.00, representing about 72.3% upside from its current price of $12.77.Amount of Analyst CoverageTonix Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Tonix Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tonix Pharmaceuticals are expected to grow in the coming year, from ($9.94) to ($6.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tonix Pharmaceuticals is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tonix Pharmaceuticals is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTonix Pharmaceuticals has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Tonix Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.85% of the float of Tonix Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTonix Pharmaceuticals has a short interest ratio ("days to cover") of 7.98.Change versus previous monthShort interest in Tonix Pharmaceuticals has recently increased by 5.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTonix Pharmaceuticals does not currently pay a dividend.Dividend GrowthTonix Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment-0.45 News SentimentTonix Pharmaceuticals has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Tonix Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 19 people have searched for TNXP on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows9 people have added Tonix Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $223,350.00 in company stock, which represents 0.1097% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Tonix Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $223,350.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.00% of the stock of Tonix Pharmaceuticals is held by insiders.Percentage Held by Institutions82.26% of the stock of Tonix Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tonix Pharmaceuticals' insider trading history. Receive TNXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TNXP Stock News HeadlinesZacks Research Issues Negative Forecast for TNXP EarningsMay 25 at 1:10 AM | americanbankingnews.comTNXP: Secures commercial payer coverage for Tonmya® to provide access for ~35 million US patientsMay 22 at 8:12 AM | msn.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 25 at 1:00 AM | Profits Run (Ad)TNXP: Secures Commercial Payer Coverage for Tonmya® to Provide Access for ~35 Million U.S. PatientsMay 20, 2026 | finance.yahoo.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Pass Above Two Hundred Day Moving Average - What's Next?May 19, 2026 | americanbankingnews.comTonix Pharma advances TNX-4800 Lyme vaccine programMay 15, 2026 | tipranks.comTonix Pharmaceuticals Holding (TNXP) price target decreased by 14.88% to 47.18May 14, 2026 | msn.comTonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026May 14, 2026 | finance.yahoo.comSee More Headlines TNXP Stock Analysis - Frequently Asked Questions How have TNXP shares performed this year? Tonix Pharmaceuticals' stock was trading at $15.62 at the beginning of the year. Since then, TNXP shares have decreased by 18.2% and is now trading at $12.77. How were Tonix Pharmaceuticals' earnings last quarter? Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) posted its quarterly earnings results on Monday, May, 11th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.54) by $0.39. The firm earned $6.88 million during the quarter, compared to analysts' expectations of $6.13 million. Tonix Pharmaceuticals had a negative trailing twelve-month return on equity of 67.65% and a negative net margin of 839.52%. When did Tonix Pharmaceuticals' stock split? Tonix Pharmaceuticals's stock reverse split on Wednesday, February 5th 2025.The 1-100 reverse split was announced on Monday, February 3rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Tonix Pharmaceuticals' major shareholders? Top institutional shareholders of Tonix Pharmaceuticals include Bank of America Corp DE (0.38%), Bank of New York Mellon Corp (0.23%) and SJS Investment Consulting Inc. (0.07%). Insiders that own company stock include Seth Lederman and Carolyn E Taylor. View institutional ownership trends. How do I buy shares of Tonix Pharmaceuticals? Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tonix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tonix Pharmaceuticals investors own include Meta Platforms (META), Digital Turbine (APPS), NIO (NIO), Sorrento Therapeutics (SRNE) and Company Calendar Last Earnings5/11/2026Today5/25/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (8m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 TNXP's financial health is in the Yellow zone, according to TradeSmith. TNXP has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNXP CIK1430306 Webwww.tonixpharma.com Phone(862) 799-8599Fax212-923-5700Employees50Year Founded2007Price Target and Rating Average Price Target for Tonix Pharmaceuticals$22.00 High Price Target$22.00 Low Price Target$22.00 Potential Upside/Downside+72.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($14.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$124.02 million Net Margins-839.52% Pretax Margin-839.52% Return on Equity-67.65% Return on Assets-60.47% Debt Debt-to-Equity RatioN/A Current Ratio6.99 Quick Ratio6.86 Sales & Book Value Annual Sales$17.56 million Price / Sales11.60 Cash FlowN/A Price / Cash FlowN/A Book Value$14.25 per share Price / Book0.90Miscellaneous Outstanding Shares15,941,000Free Float15,622,000Market Cap$203.57 million OptionableNot Optionable Beta1.68 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:TNXP) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
